1 12 月, 2022

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

TOKYO, Dec 1, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10. Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:- Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.- Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts. "We continue to relentlessly pursue research that provides useful insights for people living with breast cancer," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin." This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.For more information, visit www.eisai.com/news/2022/news202286.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

6 12 月, 2021

Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 6, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, "eribulin"), MORAb-202, an antibody drug conjugate (ADC), and H3B-6545 (selective estrogen alpha receptor covalent antagonist), discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be given at the 44th San Antonio Breast Cancer Symposium (SABCS2021) to be held, partly virtual, from December 7 to 10, 2021, in San Antonio, Texas in the United States.At this symposium, regarding eribulin, the result of non-clinical studies on its effects to subsequent chemotherapy through the induction of epithelial-mesenchymal transition (Abstract No: P3-06-01) is scheduled to be presented.MORAb-202 is Eisai's first ADC and combines Eisai's in-house developed anti-folate receptor alpha (FR) antibody, to Eisai's anticancer agent eribulin, using an enzyme cleavable linker. At this symposium, regarding MORAb-202, the experimental results of antitumor efficacy in Patient-Derived Xenograft models of triple-negative breast cancer (Abstract No: P5-08-02) is scheduled to be presented. In June 2021, Eisai and Bristol-Myers Squibb Company (Headquarters: the United States) entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202.In addition, regarding H3B-6545, the results of Phase II clinical study evaluating monotherapy (Abstract No: P1-17-10) and Phase 1b study evaluating the combination therapy with palbociclib (Abstract No: P1-17-03) in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer will be presented.Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai is aspiring to making further contribution to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers through creating innovative new drugs based on cutting-edge cancer research.This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

27 5 月, 2021

Football: Conte leaves Italian champions Inter by ‘mutual consent’

MILAN (AFP) - Antonio Conte has parted company with newly-crowned Serie A champions Inter Milan after leading them to a first title in 11 years, the Italian club confirmed on Wednesday (May 26). "FC Internazionale Milano can confirm that an agreement has been reached with Antonio Conte for the termination of his contract by mutual consent," the Chinese-owned club said in a statement. The former Chelsea and Juventus boss took over in May 2019 on a three-year contract worth a reported €12 million (S$19 million) a season. "The club would like to thank Antonio for the extraordinary work that he has done, culminating in Inter's 19th top-flight title. Antonio Conte will forever remain a part of our club's history." The 51-year-old Italian has been at loggerheads with the cash-strapped club's owners Suning over planned cost cutting which would prevent him building the team he wants to challenge at home and in Europe. Inter registered losses of €100 million last season mainly due to the coronavirus pandemic. The Suning Group shut down their Chinese club Jiangsu FC in February months after it won the Chinese Super League title. Five days ago, Inter secured a cash injection worth €275 million with US investment firm Oaktree, in the form of a loan reported to be over three years. Suning wants to save as much as possible both on the purchase of new players and salaries, as well as potentially selling those with the highest value, an approach that Conte believes incompatible with the club's desire to play at the highest level in Europe. His departure had also been heralded last summer after the club's Europa League final defeat to Sevilla and second-place finish in the league behind Juventus. Conte had blamed the club's lack of investment on their failure to challenge this season in the Champions League, in which they have crashed out in the group stage in each of the last three seasons. More on this topic Related Story Football: Inter crowned Serie A champions for 19th time as Atalanta held, Juve's nine-season streak ends Related Story Football: Conte to remain Inter Milan coach next season

1 1 月, 2021

Hammon popping into role a ‘big deal’

SAN ANTONIO • San Antonio Spurs assistant coach Becky Hammon made history on Wednesday, becoming the first woman to take charge of a National Basketball Association (NBA) team when she took over after long-serving head coach Gregg Popovich was ejected. Popovich received two technical fouls with 3 minutes and 56 seconds left in the second quarter of the Spurs' eventual 121-107 defeat by the visiting Los Angeles Lakers, leading to Hammon stepping in. "I did not walk into the arena thinking I would be coaching tonight, but that's the way things go and you roll with it, and I would have liked a different outcome," the 43-year-old said. "Overall, I would have loved to get a win tonight more than anything." She did not know she would be put in charge until her boss made the call. "He officially pointed at me," she said. "That was it. He said, 'You got 'em.' That was it. Very Pop-like." San Antonio trailed by 11 points when Popovich was tossed and while all the attention was on Hammon, she insisted she could not have done it alone. "We all group together, (assistant coaches) Will Hardy, Mitch Johnson, (like) 'What can we do to help?'" she said. "It was a great team effort, and they are in my ear giving me suggestions and helping with substitutions and whatnot. "When Pop gets tossed, we all come together and become kind of another team." Hammon has been an assistant coach for the Spurs since August 2014, the first woman to be paid for that job in an official, full-time capacity. The former guard had a 16-year playing career in the Women's National Basketball Association and while LeBron James spoiled her debut on what was his 36th birthday, Hammon was still proud of her acting role. "Obviously it's a big deal, a substantial moment," she said. "I've been a part of this organisation. I got traded here in 2007, so I've been in San Antonio and part of the Spurs... organisation with the (San Antonio) Stars and everything for 13 years. "So I have a lot of time invested, and they have a lot of time invested in me in building me and getting me better." James had a team-high 26 points as he set another NBA milestone, scoring double-digit points for the 1,000th straight game. On his latest achievement, the Finals Most Valuable Player said: "I just try to live in the moment and just try to continue to get better with my game, try to get better with my teammates and try to just maximise when I'm on the floor. "I've been blessed to play the game that I love for 18 years and hopefully, I can continue to play at a high level." AGENCE FRANCE-PRESSE, REUTERS